# Safety and Efficacy of Resticutis Compared to Platelet-Poor Plasma for Treating Diabetic Foot Ulcers

> **NCT02989961** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hanan Jafar** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **OTHER:** Resticutis
- **OTHER:** Platelet-Poor Plasma (PPP)

## Key facts

- **NCT ID:** NCT02989961
- **Lead sponsor:** Hanan Jafar
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-11-15
- **Primary completion:** 2018-03-13
- **Final completion:** 2019-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02989961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02989961, "Safety and Efficacy of Resticutis Compared to Platelet-Poor Plasma for Treating Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02989961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*